Bright Minds Biosciences Provides Scientific Update
Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022 VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy […]
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has filed its final patent application with the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO) for one of its lead drug candidates, […]
